ER/PR positive breast cancer by histologic assessment was predicted to be more sensitive to Fulvestrant (an ER degrader, p < 0.0001) and HER2 positive breast cancer by histologic assessment was predicted to be more sensitive to Lapatinib (p < 0.0001). Here, ERBB2 is linked to breast cancer.